Retrovirus insertion site analysis following in vivo drug selection in a phase I clinical trial utilizing G156A MGMT for enhanced chemotherapy of advanced malignancies.

被引：0
|
作者：
Sweeney, CL
Lingas, K
Reese, JS
Flick, S
Gerson, SL
机构：
[1] Case Western Reserve Univ, Case Comprehens Canc Ctr, Ctr Stem Cell & Regenerat Med, Cleveland, OH 44106 USA
[2] Univ Hosp Cleveland, Ireland Canc Ctr, Clin Trials Unit, Cleveland, OH 44106 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3048
引用
收藏
页码：853A / 853A
页数：1
相关论文
共 3 条
  • [1] Preliminary results of a phase I trial using retroviral gene transfer of G156A MGMT to protect hematopoiesis during BG and BCNU therapy of advanced malignancies
    Reese, J
    Lingas, K
    Ksenich, P
    Sweeney, C
    Koc, O
    Gerson, S
    MOLECULAR THERAPY, 2004, 9 : S385 - S385
  • [2] Safety of MGMT gene transfer into hematopoictic progenitors: A phase I clinical trial using retroviral gene transfer of G156A MGMT to protect hematopoiesis during BG plus alkylating agent treatment of advanced malignancies
    Reese, Jane S.
    Lingas, Karen T.
    Sweeney, Colin L.
    Brell, Joanna M.
    Gerson, Stanton L.
    BLOOD, 2007, 110 (11) : 154A - 154A
  • [3] Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells
    Brentjens, Renier J.
    Hollyman, Daniel
    Park, Jae
    Santos, Elmer
    Yeh, Raymond
    Stefanski, Jolanta
    Taylor, Clare
    Weiss, Mark A.
    Filippa, Daniel
    Riviere, Isabelle
    Sadelain, Michel W.
    BLOOD, 2009, 114 (22) : 1335 - 1335
1